ArticleHealth science reports2026
Mpox (Monkeypox) in Pregnancy Updates.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mpox is a zoonotic viral disease caused by the monkeypox virus, with potential for significant morbidity across all population groups, including pregnant individuals and neonates. Pregnancy represents an immunologically vulnerable state, rendering affected mothers more susceptible to severe disease progression. Objective: To provide obstetricians and maternal-fetal medicine specialists with an updated synthesis of the clinical presentation, adverse outcomes, and evidence-based management strategies for Mpox infection during pregnancy. Methods: A comprehensive literature search was conducted across multiple electronic databases-Web of Science, PubMed, Scopus, ScienceDirect, ProQuest, Cochrane Library, SAGE, Springer, and Google Scholar-for peer-reviewed studies addressing Mpox infection in pregnancy. Additionally, international guidelines and consensus statements were reviewed, including those from the World Health Organization (WHO), Royal College of Obstetricians and Gynecologists (RCOG), Centers for Disease Control and Prevention (CDC), Society for Maternal-Fetal Medicine (SMFM), and American College of Obstetricians and Gynecologists (ACOG). Results: Mpox infection during pregnancy is associated with a spectrum of adverse maternal and perinatal outcomes. Pregnant individuals are at increased risk for disease exacerbation, necessitating hospitalization and intensive care. Documented perinatal complications include spontaneous miscarriage, preterm prelabour rupture of membranes (PPROM), preterm birth, intrauterine fetal demise, congenital Mpox infection, low birth weight, and neurodevelopmental delays. Conclusion: Pregnant individuals diagnosed with Mpox should be prioritized for hospital admission, isolation, antiviral therapy, and continuous monitoring of maternal and fetal well-being. Multidisciplinary coordination is essential to mitigate risks and optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.